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ABSTRACT 
Pseudohypoaldosteronism type 1 (PHAl) is an uncommon inher- 
ited disorder characterized by salt-wasting in infancy arising from 
target organ unresponsiveness to mineralocorticoids. Clinical expres- 
sion of the disease varies from severely affected infants who may die 
to apparently asymptomatic individuals. Inheritance is Mendelian 
and may be either autosomal dominant or autosomal recessive. A 
defect in the mineralocorticoid receptor has been implicated as a likely 
cause of PHAl. The gene for human mineralocorticoid receptor (MLR) 
has been cloned and physically mapped to human chromosome 
4q31.1-31.2. The etiological role ofMLR in autosomal recessive PHAl 
was investigated by performing linkage analysis between PHAl and 
three simple sequence length polymorphisms (D4S192,0431548, and 
043413) on chromosome 4q in 10 consanguineous families. Linkage 
analysis was carried out assuming autosomal recessive inheritance 
with full penetrance and zero phenocopy rate using the MLINK pro- 
gram for two-point analysis and the HOMOZ program for multipoint 
analysis. Lod scores of less than -2 were obtained over the whole 
region from D45’192 to 048413 encompassing MLR. This provides 
evidence against MLR as the site of mutations causing PHAl in the 
majority of autosomal recessive families. (J Clin Endocrinol Metab 
80: 3341-3345, 1995) 
P SEUDOHYPOALDOSTERONISM type 1 (PHAI) is an uncommon inherited disorder characterized by salt 
wasting in infancy and associated with failure to thrive, 
hyponatremia, and hyperkalemia (1,2). Marked elevation of 
serum aldosterone levels is present in all cases, and PRA is 
increased in most (3). Patients are unresponsive to miner- 
alocorticoids, but respond to salt supplementation which can 
often be discontinued after infancy. Since the first report by 
Cheek and Perry in 1958 (4), over 100 cases have been re- 
ported. 
Clinical expression of the disease varies from severely 
affected infants who may die to apparently asymptomatic 
individuals (5). This depends in part on whether mineralo- 
corticoid resistance is confined to renal tubules (renal form) 
or involves multiple target organs, including sweat and sal- 
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ivary glands and colon (generalized form). Inheritance is 
Mendelian and may be either autosomal dominant or reces- 
sive (6,7). It has been suggested that the renal form is usually 
milder and is inherited as an autosomal dominant (AD) trait. 
Families with the generalized form are usually more severely 
affected and display an autosomal recessive (AR) inheritance 
with an increased incidence of consanguinity. 
The molecular basis of PHAl is unknown. Cheek and 
Perry suggested that “the disorder may be due to a refractory 
state on the part of the renal tubules to endogenous miner- 
alocorticoids,” an end-organ hormone insensitivity syn- 
drome. A primary defect in the human mineralocorticoid 
receptor (hMR) has remained the most plausible hypothesis 
for the molecular basis of PHAl. Since Albright’s description 
of pseudohypoparathyroidism in 1942 (81, many hormone 
resistance syndromes have been described. These include 
resistance to insulin, androgens, vitamin D, cortisol, T,, and 
vasopressin. Causative mutations have been described in 
several members of the steroid receptor superfamily of 
genes, including those for androgen, calcitriol, and glucocor- 
ticoids. 
In 1985, Armanini and co-workers demonstrated reduced 
or absent binding sites for tritiated aldosterone in circulating 
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mononuclear lymphocytes in three patients with PHAl (9, 
10). These observations have been confirmed in subsequent 
studies (11-13) and provide evidence in favor of a defect in 
hMR in PHAl. However, the possibility exists that they may 
represent a secondary effect of down-regulation due to high 
aldosterone levels. 
Molecular cloning of a complementary DNA (cDNA) en- 
coding hMR (14) has allowed a direct genetic approach to 
evaluating the hypothesis that PHAl arises from mutations 
in the gene for this receptor. Analysis has been carried out by 
3 independent groups on 7 patients, including the original 
sporadic case of Cheek and Perry. In this patient and his 
family, Southern blot analysis using 3 probes from the hMR 
cDNA revealed bands of normal size and intensity (15). In 
another patient and his family, hMR cDNA was amplified 
using 11 pairs of oligonucleotide primers, and total ribonu- 
cleic acid from peripheral blood leukocytes was amplified by 
reverse transcriptase-polymerase chain reaction (PCR). Se- 
quencing of the products showed no deviation from the 
wild-type sequence (16). Similar results were reported in a 
study of 5 other patients with PHAl (17,18). Sequencing of 
the patient’s hMR cDNA identified a nonconservative ho- 
mozygous base change in 4 of the 5 patients, and 1 of them 
had an additional conservative heterozygous base change. 
Both of these base changes were in the immunogenic domain 
and were also found to be present in a considerable number 
of normal individuals. It was concluded that these sequence 
variations did not have any pathological significance. The 
sequences of the first untranslated exon, 0.9 kilobase of the 
5’-regulatory region, and the DNA- and ligand-binding re- 
ceptor domain in these 5 patients were all normal. Full eval- 
uation of the gene for hMR (MIX) by direct mutational anal- 
ysis awaits characterization of its genomic organization. 
These results do not, of course, exclude MLR as the site of 
mutations causing PHAI, particularly in the recessive vari- 
ety, as genetic (locus or allelic) heterogeneity may exist. 
Homozygosity mapping provides a powerful approach to 
testing the role of a candidate gene in a rare autosomal 
recessive disorder with a high level of parental consanguin- 
ity (19). MLR has been mapped to human chromosome 4 by 
somatic cell hybridization and regionally localized to 4q31 .l- 
31.2 by in situ hybridization (20, 21). Linkage analysis was, 
therefore, carried out in 10 inbred families (see Fig. 1) using 
3 simple sequence length polymorphisms spanning the MLR 
region. 
Subjects and Methods 
Patients and families 
Ascertainment of families has been achieved through collaboration 
with the physicians who had reported cases of PHAl in the literature and 
British pediatric endocrinologists or nephrologists who care for children 
with PHAl. The 10 families included in this study are shown in Fig. 1. 
All parents are consanguineous (all were first cousins except in 2 fam- 
ilies), and autosomal recessive inheritance is assumed. There were 2 
affected individuals in 6 of the families. The study includes a total of 39 
individuals, 14 of whom were affected (5 males and 9 females). 
Diagnosis was made according to standard and clinical biochemical 
criteria. All affected individuals had documented elevated urinary so- 
dium in the presence of hyponatremia, hyperkalemia, increased PRA, 
elevated serum aldosterone level, and normal renal and adrenal func- 
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FIG. 1. PI-IA1 pedigrees used for linkage analysis. All affected indi- 
viduals are offsprings of marriages between first cousins, except in 
two families (010 and 012) as shown. 
tion. Probands in 7 of the 10 families (families 002,003,008,009,010,011, 
and 012) have documented evidence of generalized involvement, i.e. 
elevated sodium in sweat, saliva, or stool. In the other 3 families, the 
spectrum of organ involvement other than renal has not been fully 
evaluated. Details of individuals 003 IV-3 (2), 008 IV-5 (7), 009 IV-2 (22), 
009 IV-3 (22), OlO-IV (23), 012 V-l (6), and 012 V-2 (6) have been reported 
previously. 
DNA analysis /marker typing 
DNA was extracted from white cells by standard protocols (24). The 
primer sequences and conditions for the three markers (045192, 
D4S1548, and D4S413) have been described previously (25, 26). DNA 
was amplified by PCR and labeled by incorporating [a-32P]deoxynucle- 
otide. PCR was performed in 36-well microtiter plates (Hybaid). Each 
well contained 50-100 ng genomic DNA; 1.5 mmol/L MgCI,; 1 X re- 
action buffer 116 mM (NH,),SO,, 67mM Tris-HCI (pH 8.8 at 25 C), 0.01% 
Tween-20; Bioline, UK]; 200 pmol/L each of deoxy (d)-GTP, dATP, and 
dTTP; 20 pmol/L dCTP; 0.05 PL [3’P]dCTP (3000 Ci/mmol); 50 ng of 
each primer; and 0.2 U BIOTAG polymerase (Bioline) in a total volume 
of 20 ~1. Thirty cycles were performed in a thermocycler (Hybaid Om- 
nigene, Hybaid Ltd, UK). Alleles were separated by 6% polyacrylamide 
gel electrophoresis and detected by autoradiography. 
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Linkage analysis 
The maps used in the chromosome 4q analysis were from the reports 
of NIH/CEPH Collaborative Mapping Group (25), Gyapay et al. (26), 
and Mills et al. (27). The relative positions of MLR and the three simple 
sequence length polymorphisms used (D4S192, 0451548, and D4S413) 
are shown in Fig. 2. Linkage analysis was carried out assuming a fully 
penetrant autosomal recessive inheritance with a disease allele fre- 
quency of 0.0002 and a zero phenocopy rate. Lod scores ( logarithms to 
the base 10 of odds that two loci are linked) were calculated using the 
MLINK (~5.1) program (28) for two-point analysis and the HOMOZ 
program (29) for multipoint analysis. The markers were assumed to have 
five alleles of equal frequencies. Apparently normal siblings were not 
included in the analysis. 
Results 
The alleles of the affected individuals at the three loci 
studied are shown in Table 1. Loci were homozygous on only 
10 of 41 occasions among the 14 affected individuals typed 
at the 3 markers (2 for D4SZ92, 4 for 0451548, and 4 for 
045413 were homozygous). The 2-point lod scores are shown 
in Table 2. The lod score was less than -2 for at least 10 
centimorgans (CM) around D4S192 and D4S413 and for 5 CM 
around D4S1548. The results of the multipoint analysis are 
shown in Fig. 3. A lod score of less than -2 was obtained over 
the whole region from D4SZ92 to 045413. 
Discussion 
These results provide strong genetic evidence against MLR 
as the site of mutations causing pseudohypoaldosteronism in 
these families. Linkage analysis in inbred families provides 
a powerful strategy for examining the role of a candidate 
gene and for identifying the true location of the gene(s) 
causing this disease. Aspects of the interpretation of the 
linkage data and consideration of the possible nonreceptor 
molecular defects underlying AR PHAl and strategies for 
future investigations are discussed below. 
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FIG. 2. Physical and genetic maps of human chromosome 4q indi- 
cating relative positions of MLR and marker loci D4S192,0491548, 
and 049413. The map information shown is a composite of published 
data: a, Refs. 20,21, and 27; b, Refs. 25 and 27; and c, Ref. 26. Genetic 
distance is sex averaged and calculated using the Kosambi function. 
TABLE 1. Alleles at marker loci D4S192, D4S1548, and D4S413 
in affected individuals 
Family PWSXI 
002 II-2 
003 II-3 
004 II-1 
004 II-2 
006 II-2 
007 II-1 
008 II-5 
009 II-2 
009 II-3 
010 v-4 
011 II-1 
011 II-2 
012 V-l 
012 v-2 
D4S192 D4S1548 
12 13 
45 12 
44 22 
44 22 
14 14 
23 44 
34 22 
24 34 
24 34 
35 -a 
23 34 
23 34 
12 13 
12 13 
D4S413 
55 
11 
13 
23 
35 
15 
13 
24 
24 
24 
33 
33 
23 
23 
n Unavailable because of failure of amplification. 
TABLE 2. Two-point lod scores between PI%41 and marker loci 
on 4q 
Lod score at recombination fraction (0) 
0.00 0.01 0.05 0.10 0.20 0.30 
PHAl-D4S192 -21.16 -8.38 -2.89 -1.04 0.03 0.12 
PHAl-D4S1548 - 12.08 -4.21 -0.71 0.33 0.71 0.49 
PHAl-D4S413 --SC -7.25 -2.40 -0.78 0.13 0.21 
Genetic Distance (CM) 
-10 -5 0 5 10 15 20 25 
FIG. 3. Multipoint analysis around the MLR locus region. 
The increased incidence of rare recessive diseases in the 
offspring of consanguineous matings arises in general from 
affected individual inheriting disease alleles at a particular 
locus from a common ancestor. The affected individual is, 
therefore, said to be homozygous by descent (rather than by 
state) for the disease allele. This increases the power of link- 
age data from consanguineous families, a factor exploited in 
the strategy of homozygosity mapping of disease loci in rare 
recessive disorders (see below) (19). However, the possibility 
of a disease chromosome being introduced into a consan- 
guineous family by a married-in unrelated member cannot 
be totally excluded. This could produce an affected individ- 
ual who may be heterozygous at the disease locus. This is 
extremely unlikely, especially if the disease is rare, as is 
PHAl. Exclusion of a candidate gene is definitively achieved 
by following the segregation of an intragenic polymorphism, 
which allows identification of obligate recombinants within 
families with at least two affected children. As an informative 
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intragenic polymorphism for MLR is not currently available, 
microsatellite loci spanning the region harboring MLR were 
used. 
The genetic localization of MLR has not been well estab- 
lished. Little genetic data for MLR are available, and there- 
fore, some uncertainty exists concerning the genetic distance 
between MLR and the loci analyzed. MLR has been physi- 
cally mapped to 4q31.1-31.2 by fluorescent in situ hybrid- 
ization. Composite data from existing genetic linkage maps 
provide good evidence that D4S192 and D4S413 flank the 
region to which MLR maps, and D4Sl548 is close to the MLR 
locus. The genetic distance between D4S192 and D4S413 is 
about 18 CM. Analysis of allele data at the 3 loci by 3 parallel 
approaches provides significant evidence against a locus for 
PHAl in this region. Direct inspection reveals homozygosity 
of affected individuals on 10 of 41 occasions only. The av- 
erage region of homozygosity expected around the disease 
locus in affected offspring of a first cousin marriage is at least 
15 CM (19). Pairwise linkage analysis generates lod scores of 
-2 (the threshold accepted for exclusion assuming locus 
homogeneity) for regions around each locus totalling 25 CM. 
This includes the putative location of MLR. Finally, linkage 
analysis incorporating data from the 3 loci simultaneously 
using the program HOMOZ generates lod scores in the ex- 
clusion range for a total of at least 35 CM encompassing MLR. 
These results demonstrate that MLR is not a common site 
of mutations causing PHAl in this group of families. They do 
not exclude the possibility that MLR is the disease locus in 
a minority of these families or that a set of linked families 
might be identified if a much larger resource of AR PHAl 
families was studied. Moreover, they do not exclude MLR as 
the locus accounting for PHAl in those families that appear 
to display AD inheritance, although it is well recognized that 
allelic heterogeneity can account for variations in the mode 
of inheritance of diseases arising from a single locus. The 
evidence arising from cDNA analyses in sporadic patients 
does not, however, support MLR as the site of mutation in 
patients who may fall into the AD category, although the 
possibility that mutations exist in noncoding regulatory re- 
gions has not been excluded. 
These observations indicate that MLR is not the site of mu- 
tations causing PHAl in at least some patients. This is consistent 
with the observation that nonreceptor defects account for a 
proportion of cases in several hormone insensitivity syn- 
dromes, including androgen insensitivity (30), familial glu- 
cocorticoid deficiency (311, and pseudohypoparathyroidism 
(32). The likely molecular complexity underlying aldosterone 
function does, of course, provide numerous possible sites at 
which hormone insensitivity might arise. There is now good 
evidence that aldosterone exerts an immediate effect on its 
target cells via a membrane-bound receptor (now known as 
nongenomic action) (33). This is followed by the classical 
genomic action of aldosterone, which is thought to act by bind- 
ing to the cytoplasmic mineralocorticoid receptor, forming an 
active complex. This complex initiates protein synthesis (aldo- 
sterone-induced proteins) by binding to a number of hormone 
response element of the nuclear DNA. 
Many different hypotheses for nonreceptor defects in 
PHAl have been proposed. The nongenomic actions of min- 
eralocorticoids allow for dysfunction in pathways that do not 
include the cytoplasmic receptor. At the prereceptor level, 
there could be interference with aldosterone binding, by 
competition for the binding site or by cleavage of the recep- 
tor. At the postreceptor level, the most obvious candidates 
include the aldosterone-induced proteins, which include 
subunits of Na/K-adenosine triphosphatase and the amilo- 
ride-sensitive epithelial Na channels. Liddle’s syndrome, or 
pseudoaldosteronism, has recently been shown to arise from 
mutations in the P-subunit of the epithelial Na channel gene 
causing excessive sodium reabsorption and hypertension at 
normal or low levels of circulating aldosterone (34). In so far 
as these features represent a mirror image of PHAI, it is 
conceivable that mutations involving these sodium channels 
may render them nonfunctional or unresponsive to aldoste- 
rone. 
Homozygosity mapping represents a powerful strategy 
for examining the role of additional candidate genes in 
PHAl. This is being pursued using the present family re- 
source in parallel with a genome search using anonymous 
microsatellite loci in case the causative locus is an as yet 
unidentified gene. Identification of the gene for PHAl will 
allow improved diagnosis and treatment in affected indi- 
viduals. It should also provide new insights into the biology 
of mineralocorticoid function at a molecular level, informa- 
tion of potential value in understanding more common dis- 
ease states such as hypertension. 
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